|
Diagnosis and Evaluation
| Etiology and Pathogenesis
> Molecular
Oncology | Staging and Prognosis
|
|
Clinical Cancer Research Vol. 12, 5698-5704, October 1, 2006
|
|
|
|
|
Abstract |
|
|
|
YKL-40 and Matrix Metalloproteinase-9
as Potential Serum Biomarkers for Patients with High-Grade Gliomas
Adília Hormigo2,
Bin Gu1, Sasan Karimi3,
Elyn Riedel4, Katherine
S. Panageas4, Mark
A. Edgar5, Meena
K. Tanwar6, Jasti
S. Rao7, Martin
Fleisher1, Lisa
M. DeAngelis2 and Eric
C. Holland2,6
Authors' Affiliations: 1Clinical
Laboratories, Departments of 2Neurology, 3Radiology,
4Epidemiology and Biostatistics, 5Pathology, and
6Cancer Biology and Genetics, Neurosurgical Service,
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New
York, New York; and 7Department of Biomedical and
Therapeutic Sciences, College of Medicine, University of Illinois,
Peoria, Illinois -- Requests for reprints: Adília Hormigo, Department
of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York
Avenue, New York, NY 10021. Phone: 212-639-7330; Fax: 917-432-2310;
E-mail: hormigoa@mskcc.org.
|
|
|
|
|
Purpose. Biomarkers can
facilitate diagnosis, monitor treatment response, and
assess prognosis in some patients with cancer.
YKL-40 and matrix metalloproteinase-9 (MMP-9) are two proteins highly
differentially expressed by malignant gliomas.
We obtained prospective longitudinal serum samples from
patients with gliomas to determine whether YKL-40 or MMP-9
could be used as serum markers.
Experimental Design.
Serum samples were obtained concurrently with magnetic
resonance imaging scans.
YKL-40 and MMP-9 were determined by ELISA and the values
correlated with the patient's radiographic status and
survival.
Results. High-grade
glioma patients who underwent a surgical resection of their
tumor had transient increase of both YKL-40 and MMP-9 serum
levels in the postoperative period.
Glioblastoma multiforme (GBM) patients with no radiographic
evidence of disease (n = 10 patients, 50 samples)
had a significantly lower level of YKL-40 and MMP-9 than
patients with active tumor (n = 66 patients, 209
samples; P = 0.0003 and 0.0002, respectively).
Anaplastic glioma patients with no radiographic evidence of disease
(n = 32 patients, 107 samples) also had a significantly lower
level of YKL-40 compared with those patients with active tumor
(n = 48 patients, 199 samples; P = 0.04).
There was a significant inverse association between YKL-40
and survival in GBM, hazard ratio (hazard ratio, 1.4; P
= 0.02), and anaplastic astrocytoma patients (hazard ratio,
2.2; P = 0.05).
Conclusions. YKL-40 and
MMP-9 can be monitored in patients' serum and help confirm
the absence of active disease in GBM and YKL-40 in
anaplastic glioma patients.
YKL-40 can be used as predictor of survival in patients
with high-grade glioma.
Longitudinal studies with a larger patient population are needed to
confirm these findings.
|
|
|
|
|
© 2006 American Association for Cancer
Research
|
|
|
.JPG)
Abstract
| .png)
Reprint
|
|
|
|
